Insider Selling: Amgen Inc. (AMGN) EVP Sells 1,525 Shares of Stock
Amgen Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the sale, the executive vice president now owns 57,631 shares in the company, valued at $9,888,326.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Amgen Inc. (NASDAQ AMGN) traded down $0.85 during midday trading on Tuesday, reaching $171.50. The company’s stock had a trading volume of 2,120,100 shares, compared to its average volume of 3,249,994. Amgen Inc. has a 1-year low of $138.83 and a 1-year high of $191.10. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. The stock has a market cap of $123,500.00, a PE ratio of 13.70, a P/E/G ratio of 2.50 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business had revenue of $5.77 billion during the quarter, compared to analysts’ expectations of $5.75 billion. During the same quarter last year, the business posted $3.02 EPS. The business’s revenue was down .7% on a year-over-year basis. equities analysts forecast that Amgen Inc. will post 12.66 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Friday, November 17th will be issued a $1.15 dividend. This represents a $4.60 annualized dividend and a yield of 2.68%. The ex-dividend date of this dividend is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is currently 41.55%.
COPYRIGHT VIOLATION NOTICE: This article was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/14/insider-selling-amgen-inc-amgn-evp-sells-1525-shares-of-stock.html.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Financial Advisory Service Inc. lifted its holdings in Amgen by 0.3% in the 2nd quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after buying an additional 5 shares during the period. Jackson Grant Investment Advisers Inc. lifted its holdings in Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares during the period. Capital Advisors Ltd. LLC lifted its holdings in Amgen by 0.6% in the 2nd quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after buying an additional 7 shares during the period. Ballentine Partners LLC lifted its holdings in Amgen by 0.3% in the 2nd quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after buying an additional 9 shares during the period. Finally, Hudock Capital Group LLC lifted its holdings in Amgen by 0.5% in the 2nd quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after buying an additional 10 shares during the period. Institutional investors and hedge funds own 78.20% of the company’s stock.
A number of brokerages have weighed in on AMGN. Argus lowered Amgen from a “buy” rating to a “hold” rating and upped their target price for the stock from $175.22 to $195.00 in a research note on Wednesday, November 1st. Zacks Investment Research lowered Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Mizuho set a $198.00 target price on Amgen and gave the stock a “buy” rating in a research note on Sunday, October 29th. BMO Capital Markets restated a “market perform” rating and issued a $198.00 target price on shares of Amgen in a research note on Thursday, October 26th. Finally, Morgan Stanley decreased their target price on Amgen from $196.00 to $193.00 and set an “overweight” rating on the stock in a research note on Thursday, October 26th. Thirteen research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $190.03.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.